These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 35493453)

  • 61. Absence of inducible costimulator on alloreactive T cells reduces graft versus host disease and induces Th2 deviation.
    Hubbard VM; Eng JM; Ramirez-Montagut T; Tjoe KH; Muriglan SJ; Kochman AA; Terwey TH; Willis LM; Schiro R; Heller G; Murphy GF; Liu C; Alpdogan O; van den Brink MR
    Blood; 2005 Nov; 106(9):3285-92. PubMed ID: 15956289
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Outcome of T-cell-replete haploidentical stem cell transplantation improves with time in adults with acute lymphoblastic leukemia: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Nagler A; Labopin M; Koc Y; Angelucci E; Tischer J; Arat M; Pioltelli P; Bernasconi P; Chiusolo P; Diez-Martin JL; Sanz J; Ciceri F; Peric Z; Giebel S; Canaani J; Mohty M
    Cancer; 2021 Jul; 127(14):2507-2514. PubMed ID: 33739471
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The effect on the proliferation and apoptosis of alloreactive T cells of cell dose in a murine MHC-mismatched hematopoietic cell transplantation model.
    Fujioka T; Taniguchi Y; Masuda T; Nishida S; Ikegame K; Kawakami M; Tsuboi A; Hosen N; Murakami M; Oji Y; Oka Y; Sugiyama H; Kawase I; Ogawa H
    Transpl Immunol; 2003; 11(2):187-95. PubMed ID: 12799203
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Short Course of Post-Transplantation Cyclophosphamide and Bortezomib for Graft-versus-Host Disease Prevention after Allogeneic Peripheral Blood Stem Cell Transplantation Is Feasible and Yields Favorable Results: A Phase I Study.
    Al-Homsi AS; Cole K; Bogema M; Duffner U; Williams S; Mageed A
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1315-20. PubMed ID: 25765556
    [TBL] [Abstract][Full Text] [Related]  

  • 65. CTLA4Ig in an Extended Schedule along with Sirolimus Improves Outcome with a Distinct Pattern of Immune Reconstitution Following Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation for Hemoglobinopathies.
    Jaiswal SR; Bhakuni P; Aiyer HM; Soni M; Bansal S; Chakrabarti S
    Biol Blood Marrow Transplant; 2020 Aug; 26(8):1469-1476. PubMed ID: 32428732
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Programming of donor T cells using allogeneic δ-like ligand 4-positive dendritic cells to reduce GVHD in mice.
    Mochizuki K; Meng L; Mochizuki I; Tong Q; He S; Liu Y; Purushe J; Fung H; Zaidi MR; Zhang Y; Reshef R; Blazar BR; Yagita H; Mineishi S; Zhang Y
    Blood; 2016 Jun; 127(25):3270-80. PubMed ID: 27143255
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Multiple Myeloma.
    Ghosh N; Ye X; Tsai HL; Bolaños-Meade J; Fuchs EJ; Luznik L; Swinnen LJ; Gladstone DE; Ambinder RF; Varadhan R; Shanbhag S; Brodsky RA; Borrello IM; Jones RJ; Matsui W; Huff CA
    Biol Blood Marrow Transplant; 2017 Nov; 23(11):1903-1909. PubMed ID: 28711728
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Effector memory CD4+ T cells mediate graft-versus-leukemia without inducing graft-versus-host disease.
    Zheng H; Matte-Martone C; Li H; Anderson BE; Venketesan S; Sheng Tan H; Jain D; McNiff J; Shlomchik WD
    Blood; 2008 Feb; 111(4):2476-84. PubMed ID: 18045967
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Defibrotide combined with triple therapy including posttransplant cyclophosphamide, low dose rabbit anti-t-lymphocyte globulin and cyclosporine is effective in prevention of graft versus host disease after allogeneic peripheral blood stem cell transplantation for hematologic malignancies.
    Akpinar S; Kayikci O; Tekgunduz E
    Transfus Apher Sci; 2022 Feb; 61(1):103367. PubMed ID: 35120825
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide in Fanconi Anemia: Improving Outcomes with Improved Supportive Care in India.
    Uppuluri R; Swaminathan VV; Ramanan KM; Meena S; Varla H; Ramakrishnan B; Jayakumar I; Raj R
    Biol Blood Marrow Transplant; 2020 Dec; 26(12):2292-2298. PubMed ID: 32835780
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Successful Haploidentical Stem Cell Transplant With Posttransplant Cyclophosphamide for Hemophagocytic Lymphohistiocytosis.
    Kohli S; Rastogi N; Nivargi S; Thakkar D; Katewa S; Yadav SP
    J Pediatr Hematol Oncol; 2019 Apr; 41(3):e158-e160. PubMed ID: 30044345
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Posttransplantation Cyclophosphamide- and Sirolimus-Based Graft-Versus-Host-Disease Prophylaxis in Allogeneic Stem Cell Transplant.
    Greco R; Lorentino F; Albanese S; Lupo Stanghellini MT; Giglio F; Piemontese S; Clerici D; Lazzari L; Marcatti M; Mastaglio S; Xue E; Farina F; Pavesi F; Assanelli A; Carrabba MG; Marktel S; Vago L; Bonini C; Corti C; Bernardi M; Ciceri F; Peccatori J
    Transplant Cell Ther; 2021 Sep; 27(9):776.e1-776.e13. PubMed ID: 34087452
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Impact of CD34 Cell Dose and Conditioning Regimen on Outcomes after Haploidentical Donor Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide for Relapsed/Refractory Severe Aplastic Anemia.
    Arcuri LJ; Nabhan SK; Cunha R; Nichele S; Ribeiro AAF; Fernandes JF; Daudt LE; Rodrigues ALM; Arrais-Rodrigues C; Seber A; Atta EH; de Oliveira JSR; Funke VAM; Loth G; Junior LGD; Paz A; Calixto RF; Gomes AA; Araujo CES; Colturato V; Simoes BP; Hamerschlak N; Flowers ME; Pasquini R; Rocha V; Bonfim C
    Biol Blood Marrow Transplant; 2020 Dec; 26(12):2311-2317. PubMed ID: 32949751
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation.
    Mehta RS; Saliba RM; Chen J; Rondon G; Hammerstrom AE; Alousi A; Qazilbash M; Bashir Q; Ahmed S; Popat U; Hosing C; Khouri I; Shpall EJ; Champlin RE; Ciurea SO
    Br J Haematol; 2016 May; 173(3):444-55. PubMed ID: 26947769
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Haploidentical Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Post-Transplantation Cyclophosphamide Graft-versus-Host Disease Prophylaxis.
    Castagna L; Mussetti A; Devillier R; Dominietto A; Marcatti M; Milone G; Maura F; de Philippis C; Bruno B; Furst S; Blaise D; Corradini P; Montefusco V
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1549-1554. PubMed ID: 28499937
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Outcomes after Haploidentical Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Patients with Primary Immunodeficiency Diseases.
    Fernandes JF; Nichele S; Arcuri LJ; Ribeiro L; Zamperlini-Netto G; Loth G; Rodrigues ALM; Kuwahara C; Koliski A; Trennepohl J; Garcia JL; Daudt LE; Seber A; Gomes AA; Fasth A; Pasquini R; Hamerschlak N; Rocha V; Bonfim C
    Biol Blood Marrow Transplant; 2020 Oct; 26(10):1923-1929. PubMed ID: 32653621
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Increased early mortality after fludarabine and melphalan conditioning with peripheral blood grafts in haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide.
    Eastburg L; Russler-Germain DA; DiPersio JF; Fountaine T; Andolina JR; Abboud R; Huselton E
    Leuk Lymphoma; 2022 Jan; 63(1):222-226. PubMed ID: 34794373
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Selective Depletion of αβ T Cells and B Cells for Human Leukocyte Antigen-Haploidentical Hematopoietic Stem Cell Transplantation. A Three-Year Follow-Up of Procedure Efficiency.
    Li Pira G; Malaspina D; Girolami E; Biagini S; Cicchetti E; Conflitti G; Broglia M; Ceccarelli S; Lazzaro S; Pagliara D; Meschini A; Bertaina A; Montanari M; Locatelli F
    Biol Blood Marrow Transplant; 2016 Nov; 22(11):2056-2064. PubMed ID: 27519279
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Dysfunction of bone marrow vascular niche in acute graft-versus-host disease after MHC-haploidentical bone marrow transplantation.
    Yao Y; Song X; Cheng H; Tang G; Hu X; Zhou H; Wang J
    PLoS One; 2014; 9(8):e104607. PubMed ID: 25119573
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Inhibitory effect of a CD4-CDR3 peptide analog on graft-versus-host disease across a major histocompatibility complex-haploidentical barrier.
    Townsend RM; Briggs C; Marini JC; Murphy GF; Korngold R
    Blood; 1996 Oct; 88(8):3038-47. PubMed ID: 8874202
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.